Disitamab Vedotin combining with Toripalimab versus adjuvant Toripalimab in HER2 expressed high-risk MIBC patients after radical cystectomy: a prospective, multicentre, open-label, randomised, phase 3 trial

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2025
This article has no abstract
Epistemonikos ID: fb0f8393435a02a05690dc58469780515bc7f5a8
First added on: Apr 24, 2026